<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "journalpublishing3.dtd">
<article xml:lang="en" article-type="research-article" xmlns:xlink="http://www.w3.org/1999/xlink">
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Molecular Medicine Reports</journal-id>
<journal-title-group>
<journal-title>Molecular Medicine Reports</journal-title></journal-title-group>
<issn pub-type="ppub">1791-2997</issn>
<issn pub-type="epub">1791-3004</issn>
<publisher>
<publisher-name>D.A. Spandidos</publisher-name></publisher></journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3892/mmr.2013.1405</article-id>
<article-id pub-id-type="publisher-id">mmr-07-05-1417</article-id>
<article-categories>
<subj-group>
<subject>Articles</subject></subj-group></article-categories>
<title-group>
<article-title>Genome-wide analysis of DNA methylation in rat lungs with lipopolysaccharide-induced acute lung injury</article-title></title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>ZHANG</surname><given-names>XIAO-QIANG</given-names></name><xref rid="af1-mmr-07-05-1417" ref-type="aff">1</xref></contrib>
<contrib contrib-type="author">
<name><surname>LV</surname><given-names>CHANG-JUN</given-names></name><xref rid="af1-mmr-07-05-1417" ref-type="aff">1</xref></contrib>
<contrib contrib-type="author">
<name><surname>LIU</surname><given-names>XIANG-YONG</given-names></name><xref rid="af2-mmr-07-05-1417" ref-type="aff">2</xref></contrib>
<contrib contrib-type="author">
<name><surname>HAO</surname><given-names>DONG</given-names></name><xref rid="af1-mmr-07-05-1417" ref-type="aff">1</xref></contrib>
<contrib contrib-type="author">
<name><surname>QIN</surname><given-names>JING</given-names></name><xref rid="af1-mmr-07-05-1417" ref-type="aff">1</xref></contrib>
<contrib contrib-type="author">
<name><surname>TIAN</surname><given-names>HUAN-HUAN</given-names></name><xref rid="af1-mmr-07-05-1417" ref-type="aff">1</xref></contrib>
<contrib contrib-type="author">
<name><surname>LI</surname><given-names>YAN</given-names></name><xref rid="af1-mmr-07-05-1417" ref-type="aff">1</xref></contrib>
<contrib contrib-type="author">
<name><surname>WANG</surname><given-names>XIAO-ZHI</given-names></name><xref rid="af1-mmr-07-05-1417" ref-type="aff">1</xref><xref ref-type="corresp" rid="c1-mmr-07-05-1417"/></contrib></contrib-group>
<aff id="af1-mmr-07-05-1417">
<label>1</label>Department of Respiratory and Intensive Care Unit, Affiliated Hospital of Binzhou Medical University, Binzhou, Shandong 256603, P.R. China</aff>
<aff id="af2-mmr-07-05-1417">
<label>2</label>Department of Cell Biology, Binzhou Medical University, Yantai, Shandong 264003, P.R. China</aff>
<author-notes>
<corresp id="c1-mmr-07-05-1417">Correspondence to: Professor Xiao-Zhi Wang, Department of Respiratory and Intensive Care Unit, Affiliated Hospital of Binzhou Medical University, 661 Yellow River Road, Binzhou, Shandong 256603, P.R. China, E-mail: <email>respirationbzmc@yahoo.cn</email></corresp></author-notes>
<pub-date pub-type="ppub">
<month>5</month>
<year>2013</year></pub-date>
<pub-date pub-type="epub">
<day>28</day>
<month>03</month>
<year>2013</year></pub-date>
<volume>7</volume>
<issue>5</issue>
<fpage>1417</fpage>
<lpage>1424</lpage>
<history>
<date date-type="received">
<day>13</day>
<month>11</month>
<year>2012</year></date>
<date date-type="accepted">
<day>07</day>
<month>03</month>
<year>2013</year></date></history>
<permissions>
<copyright-statement>Copyright &#x000A9; 2013, Spandidos Publications</copyright-statement>
<copyright-year>2013</copyright-year>
<license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/3.0">
<license-p>This is an open-access article licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. The article may be redistributed, reproduced, and reused for non-commercial purposes, provided the original source is properly cited.</license-p></license></permissions>
<abstract>
<p>Acute lung injury and acute respiratory distress syndrome (ALI/ARDS) are associated with high morbidity and mortality in patients, however, the precise pathogenesis of ALI/ARDS remains unknown. Lipopolysaccharide (LPS) exhibits a number of critical functions and may be associated with the DNA methylation of genes in the lungs. In the present study a genome-wide analysis of DNA methylation was performed in rat lungs with LPS-induced ALI/ARDS. Normal and LPS-induced lung tissues with ALI were analyzed using methylated DNA immunoprecipitation and a rat DNA methylation promoter plus CpG island microarray and the candidate genes were validated by quantitative reverse transcriptase polymerase chain reaction (qRT-PCR). Aberrant DNA methylation of the promoter regions of 1,721 genes and the CpG islands of 990 genes was identified when normal lung tissues and lung tissues with LPS-induced ALI/ARDS were compared. These genes were commonly located on chromosomes 1, 3, 5, 7 and 10 (P&lt;0.01). Methylation level and CpG density were compared and it was found that genes associated with high CpG density promoters had a high ratio of methylation. Furthermore, we performed gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis. In addition, three genes (Mapk3, Pak1 and Rac2) were validated in the control and lung tissues with ALI by RT-PCR. The results indicate that aberrant DNA methylation of lung tissues may be involved in the pathophysiology of LPS-induced ALI/ARDS. Future studies are required to evaluate the therapeutic and prognostic value of the current novel observations in ALI/ARDS.</p></abstract>
<kwd-group>
<kwd>lipopolysaccharide</kwd>
<kwd>acute lung injury</kwd>
<kwd>acute respiratory distress syndrome</kwd>
<kwd>DNA methylation</kwd>
<kwd>promoter</kwd>
<kwd>CpG island</kwd></kwd-group></article-meta></front>
<body>
<sec sec-type="intro">
<title>Introduction</title>
<p>Acute lung injury (ALI) and its more severe form, acute respiratory distress syndrome (ARDS), characterized by non-cardiogenic pulmonary edema that results from the disruption of the alveolar-capillary barrier and pulmonary capillary permeability, are severe diseases with high clinical morbidity and mortality. Although previous studies have reported a reduction in mortality, due to the implementation of lung-protective ventilation strategies, the mortality rate remains high (~40&#x00025;) (<xref rid="b1-mmr-07-05-1417" ref-type="bibr">1</xref>,<xref rid="b2-mmr-07-05-1417" ref-type="bibr">2</xref>). One of the main pathogenetic factors is sepsis and certain studies have demonstrated that sepsis-induced ALI/ARDS is closely associated with levels of lipopolysaccharide (LPS) in plasma (<xref rid="b3-mmr-07-05-1417" ref-type="bibr">3</xref>). Systemic inflammatory response syndrome (SIRS) is induced by pro- and anti-inflammatory cytokine imbalance and has a detrimental role in LPS-induced ALI/ARDS. LPS causes the simultaneous upregulation or downregulation of the expression of specific inflammatory factors, which leads to changes in the DNA methylation of these factors. LPS induces the hypermethylation of the TNF-&#x003B1; promoter in human THP-1 monocytes. A previous study indicated that epigenetics are significant in the inflammatory process, regardless of whether it occurs locally or systemically (<xref rid="b4-mmr-07-05-1417" ref-type="bibr">4</xref>). Other studies have demonstrated that IL-8 activation in human intestinal epithelial cells is accompanied by H3K4, H3K9 and H3K27 methylation at the IL-8 gene promoter following LPS stimulation (<xref rid="b5-mmr-07-05-1417" ref-type="bibr">5</xref>). In addition, LPS induces aberrant hypermethylation of Hic-1 in mouse embryonic fibroblasts lacking p53 in culture (<xref rid="b6-mmr-07-05-1417" ref-type="bibr">6</xref>). These findings led us to hypothesize that altered DNA methylation in lung tissues may play a major role in LPS-induced ALI/ARDS.</p>
<p>Epigenetics, including DNA methylation, histone modifications and non-coding RNAs, affect the expression of individual genes, shape developmental patterns and contribute to the maintenance of cellular memory required for developmental stability and tissue-specific changes (<xref rid="b7-mmr-07-05-1417" ref-type="bibr">7</xref>). DNA methylation, as a major form of epigenetic modification, is an important mechanism for the regulation of genome function. DNA methylation has a fundamental role in the regulation of gene transcription without altering the sequence of the DNA (<xref rid="b8-mmr-07-05-1417" ref-type="bibr">8</xref>). CpG islands, defined as short DNA regions of genome containing a high frequency of CG dinucleotides, are often located in the promoter in the 5&#x02032; flanking region of housekeeping genes and a number of tissue-specific genes. Cytosines located at CpG dinucleotides catalyze this chemical modification and are targeted primarily by the DNA methyltransferase family (<xref rid="b9-mmr-07-05-1417" ref-type="bibr">9</xref>). DNA methylation regulates gene expression by inhibiting the binding of transcription factors to cognate <italic>cis</italic> elements and by facilitating the binding of methyl-CpG-binding proteins, which directly or indirectly affect the histone code and lead to chromatin condensation to inhibit transcription factor binding (<xref rid="b10-mmr-07-05-1417" ref-type="bibr">10</xref>). In previous studies, the effect of DNA methylation has been associated with cancer, cardiovascular disease, mental illness and human autoimmune diseases. Within the lungs, aberrant DNA methylation is associated with tumorigenesis (<xref rid="b11-mmr-07-05-1417" ref-type="bibr">11</xref>), airway inflammation (<xref rid="b12-mmr-07-05-1417" ref-type="bibr">12</xref>) and other diseases (<xref rid="b13-mmr-07-05-1417" ref-type="bibr">13</xref>).</p>
<p>In the current study, genome-wide analysis of DNA methylation in rat lung tissues with LPS-induced ALI/ARDS was performed using methylated DNA immunoprecipitation (MeDIP) and the Roche-NimbleGen Rat DNA methylation 385K CpG islands plus promoter arrays. Based on results of the MeDIP and arrays, associated genes and chromosomes were determined, the correlation between DNA methylation and CpG density was determined and gene ontology (GO) and pathway analysis was performed. These results are likely to provide insight into the therapy and prognosis of LPS-induced ALI/ARDS.</p></sec>
<sec sec-type="methods">
<title>Materials and methods</title>
<sec>
<title>Animals and reagents</title>
<p>Male Sprague-Dawley rats (6&#x02013;8-weeks old) weighing 180&#x02013;220 g, were obtained from the Vital River Laboratory Animal Technology Co., Ltd. (Beijing, China). All animals were allowed food and tap water <italic>ad libitum</italic>. All experimental procedures were in accordance with the Declaration of Helsinki of the World Medical Association. Protocols were also approved by the Institutional Animal Care and Use Committee of Binzhou Medical University. LPS (<italic>Escherichia coli</italic> LPS, 055:B5) was purchased from Sigma-Aldrich (St. Louis, MO, USA).</p></sec>
<sec>
<title>LPS-induced ALI animal model</title>
<p>Rats were fasted overnight but allowed water <italic>ad libitum</italic> prior to induction of ALI. Animals were anesthetized using 40 mg/kg chloral hydrate. LPS &#x0005B;10 mg/kg in phosphate-buffered saline (PBS)&#x0005D; was instilled intratracheally to induce ALI. The control group underwent the same procedure with intratracheal instillation of PBS (10 mg/kg).</p></sec>
<sec>
<title>Pulmonary histopathology</title>
<p>The lower lobe of the right lung tissue was harvested 12 h following LPS or PBS administration and fixed in 4&#x00025; paraformaldehyde for 5 days at 4&#x000B0;C. The lobe was embedded in paraffin and cut into 5-&#x003BC;m sections. Hematoxylin and eosin staining was performed according to the standard method to assess the lung injury.</p></sec>
<sec>
<title>Genomic DNA extraction and fragmentation</title>
<p>Genomic DNA was extracted from four lung tissue samples (control and LPS-induced ALI, n&#x0003D;2 each) using a DNeasy Blood and Tissue kit (Qiagen, Hilden, Germany) according to the manufacturer&#x02019;s instructions. Briefly, the lung tissue was ground using a homogenizer on ice, lysed with proteinase K and tissue lysis buffer for 3 h and then precipitated and washed. The genomic DNA quality and quantity was assessed using the Nanodrop spectrophotometer (Thermo Fisher Scientific Inc., Wilmington, DE, USA) and a A<sub>260</sub>/A<sub>280</sub> ratio between 1.7 and 2.0 was considered a criterion for quality control. The genomic DNA of each sample was sonicated between 200 and 1,000 bp with a Bioruptor sonicator (Diagenode Inc., Denville, NJ, USA) on &#x02018;LOW&#x02019; mode for 10 cycles of 30 sec &#x02018;ON&#x02019; and 30 sec &#x02018;OFF&#x02019;.</p></sec>
<sec>
<title>MeDIP and microarray analysis</title>
<p>Sonicated genomic DNA (1 &#x003BC;g) was used for immunoprecipitation with a mouse monoclonal anti-5-methylcytosine antibody (Diagenode Inc.). DNA was heat-denatured at 94&#x000B0;C for 10 min, rapidly cooled on ice and immunoprecipitated with 1 &#x003BC;l primary antibody overnight at 4&#x000B0;C with rocking agitation in 400 &#x003BC;l immunoprecipitation buffer (0.5&#x00025; BSA in PBS). A total of 200 &#x003BC;l anti-mouse IgG magnetic beads were added and the mixture was incubated to recover the immunoprecipitated DNA fragments for an additional 2 h at 4&#x000B0;C with agitation. Following immunoprecipitation, five immunoprecipitation washes were performed with ice-cold immunoprecipitation buffer. Washed beads were resuspended in TE buffer with 0.25&#x00025; sodium dodecyl sulfate (SDS) and 0.25 mg/ml proteinase K for 2 h at 65&#x000B0;C and then allowed to cool to room temperature. MeDIP DNA was purified using Qiagen MinElute columns (Qiagen). MeDIP-enriched DNA was amplified using the GenomePlex&#x000AE; Complete Whole Genome Amplification kit from Sigma-Aldrich. Amplified DNA samples were purified using the QIAquick PCR purification kit (Qiagen). Purified DNA was quantified using the ND-1000 Nanodrop. For DNA labeling, the NimbleGen Dual-Color DNA Labeling kit was used according to the manufacturer&#x02019;s instructions (NimbleGen Systems, Inc., Madison, WI, USA). The DNA (1 &#x003BC;g) of each sample was incubated for 10 min at 98&#x000B0;C with 1 OD or 40 &#x003BC;l of Cy5-9mer (MeD1P sample) or Cy3-9mer (input sample) primers. Next, 100 pmol deoxynucleoside triphosphates and 100 units Klenow fragment (New England Biolabs, Inc., Ipswich, MA, USA) were added. The mix was incubated at 37&#x000B0;C for 2 h. The reaction was terminated by adding 10 &#x003BC;l 0.5 M EDTA and the labeled DNA was purified by isopropanol/ethanol precipitation. Microarrays were hybridized at 42&#x000B0;C for 16&#x02013;20 h with Cy3/5-labeled DNA in NimbleGen hybridization buffer/hybridization component A in a hybridization chamber (Hybridization System, NimbleGen Systems). Following hybridization, washing was performed using the NimbleGen Wash Buffer kit. For array hybridization, Roche-NimbleGen&#x02019;s Rat Promoter plus CpG Island array was used. The array has a 385K format array design containing gene promoters &#x0005B;&#x02212;1,300 to &#x0002B;500 bp of the start site of the transcript (TSS)&#x0005D;. A total of 15,809 CpG islands were covered by ~385,000 probes. Array data were extracted and analyzed using NimbleScan and SignalMap software. Only genes with consistent differences between the two control and two LPS groups were considered.</p></sec>
<sec>
<title>Quantitative reverse transcription-polymerase chain reaction (qRT-PCR) confirmation of gene methylation changes</title>
<p>A MeDIP assay, combined with qPCR, was used to quantitatively evaluate the methylation status of candidate genes in the lung tissues derived from control and ALI/ARDS groups. MeDIP was performed as described. Purified DNA from the immunoprecipitated DNA complexes and the input DNA was analyzed by qRT-PCR on the ABI PRISM 7900 system (Applied Biosystems, Bedford, MA, USA). Primers used were as follows: Mapk3, forward 5&#x02032;-CCCTTCAGACTGCTTCCTCA-3&#x02032; and reverse 5&#x02032;-CTT GGGCTGTCAGACTTGGT-3&#x02032;; Pak1, forward 5&#x02032;-GAATTT GTGGTACAGCAGGACAT-3&#x02032; and reverse 5&#x02032;-CCACTGAGG CTATCTTTGACG-3&#x02032;; Rac2, forward 5&#x02032;-TTACCCATCACC CACCACC-3&#x02032; and reverse 5&#x02032;-TTCCGTTTCCTCCTGCCTC-3&#x02032;. Relative changes in gene methylation were determined by measuring the amount of detected genes in immunoprecipitated DNA following normalization against input DNA.</p></sec>
<sec>
<title>Statistical analysis</title>
<p>Data are expressed as the mean &#x000B1; SD. For the chromosome distribution of genes and the number of genes in high CpG density promoters (HCP), intermediate CpG density promoters (ICP) and low CpG density promoters (LCP), positive/negative genes were compared using the Chi-square test. P&lt;0.05 was considered to indicate a statistically significant difference (<xref rid="b14-mmr-07-05-1417" ref-type="bibr">14</xref>).</p></sec></sec>
<sec sec-type="results">
<title>Results</title>
<sec>
<title>Histological changes in lung tissues</title>
<p>No histological alterations were found in the control group (<xref rid="f1-mmr-07-05-1417" ref-type="fig">Fig. 1A and B</xref>). In the LPS-induced ALI/ARDS group, microscopic changes were observed 12 h following LPS administration. The observed inflammatory alterations were characterized by alveolar wall thickness, alveolar and interstitial edema and hemorrhage, interstitial infiltration by neutrophils and the complete consolidation of a section of the lung tissue (<xref rid="f1-mmr-07-05-1417" ref-type="fig">Fig. 1C and D</xref>).</p></sec>
<sec>
<title>Chromosomal distribution</title>
<p>LPS-induced DNA methylation alterations were initially observed in the chromosome. A total of 1,721 candidate genes methylated in the promoter region were distributed across all chromosomes (<xref rid="f2-mmr-07-05-1417" ref-type="fig">Fig. 2A</xref>). The results indicate that the gene number of the chromosomes was statistically significant: 236 genes on chromosome 1 (13.7&#x00025;, P&lt;0.01), 144 genes on chromosome 3 (8.4&#x00025;, P&lt;0.01), 115 genes on chromosome 5 (6.7&#x00025;, P&lt;0.01) and 156 genes on chromosome 10 (9.1&#x00025;, P&lt;0.01). The 990 candidate genes methylated in the CpG island were also distributed across all chromosomes (<xref rid="f2-mmr-07-05-1417" ref-type="fig">Fig. 2B</xref>). Results indicate that the gene number of the chromosomes was statistically significant: 146 genes on chromosome 1 (14.7&#x00025;, P&lt;0.01), 78 genes on chromosome 3 (7.9&#x00025;, P&lt;0.01), 72 genes on chromosome 5 (7.3&#x00025;, P&lt;0.01), 81 genes on chromosome 7 (8.2&#x00025;, P&lt;0.01) and 81 genes on chromosome 10 (8.2&#x00025;, P&lt;0.01).</p></sec>
<sec>
<title>Levels of DNA methylation in the promoters and CpG islands</title>
<p>The promoters were divided into three categories based on CG content: HCP, ICP and LCP. The methylation level and CpG density in the promoter were compared (<xref rid="f3-mmr-07-05-1417" ref-type="fig">Fig. 3A</xref>). In the group of genes in which the degree of methylation was reduced by LPS-induced ALI/ARDs, the number of methylated HCP genes was significantly higher (49.34&#x00025;, P&lt;0.01) than the numbers of methylated ICP (26.11&#x00025;) and LCP (24.56&#x00025;) genes. However, in the group of genes in which the degree of methylation was increased by LPS-induced ALI/ARDs, the numbers of methylated genes were similar in the HCP (32.39&#x00025;), ICP (32.15&#x00025;) and LCP (35.46&#x00025;) zones. In addition, differences in the methylation levels of CpG islands were noted (<xref rid="f3-mmr-07-05-1417" ref-type="fig">Fig. 3B</xref>). In the decreased group, the number of methylated HCP genes was also significantly higher (59.18&#x00025;, P&lt;0.01) than that of ICP (38.78&#x00025;) and LCP (2.04&#x00025;) genes. A similar distribution was observed in the increased group: the methylation of the HCP zone (60.26&#x00025;) was identified to be significantly higher (P&lt;0.01) than that of the ICP (26.67&#x00025;) and LCP (13.07&#x00025;) zones.</p></sec>
<sec>
<title>GO annotation and pathway analysis</title>
<p>The GO project provides a controlled vocabulary to describe gene and gene product attributes in any organism (<ext-link xlink:href="http://www.geneontology.org" ext-link-type="uri">http://www.geneontology.org</ext-link>). The ontology covers three domains: biological process, cellular component and molecular function. In the present study, GO Ontology was used to perform GO term analysis of the 1,721 genes in the methylated in the promoter region and the 990 genes methylated in the CpG island. Results indicate that the candidate genes are associated with 755 biological processes, 79 cellular components and 93 molecular functions. Genetic studies of ALI/ARDS have largely focused on candidate genes involved in the response to external stimulus, intracellular signal transduction and negative regulation of cell proliferation (<xref rid="b15-mmr-07-05-1417" ref-type="bibr">15</xref>). Therefore, all genes in the three GO terms were selected (<xref rid="tI-mmr-07-05-1417" ref-type="table">Table I</xref>). GO analysis of all candidate genes revealed 146 genes involved in the response to external stimulus, 205 genes in intracellular signal transduction and 65 genes in negative regulation of cell proliferation. Next, 14 methylated genes from the GO term results which are etiologically involved in the LPS-induced ALI/ARDS were selected (<xref rid="tII-mmr-07-05-1417" ref-type="table">Table II</xref>). The Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway database (<ext-link xlink:href="http://www.genome.jp/kegg" ext-link-type="uri">http://www.genome.jp/kegg</ext-link>) was used to perform pathway analysis of these candidate genes. The analysis divided the candidate genes into 38 signaling pathways, and the 10 enrichment pathways involved in immune and inflammatory responses were selected. The included pathways were: neuroactive ligand-receptor interaction, neurotrophin signaling pathway, MAPK signaling pathway, cholinergic synapse, mTOR signaling pathway, Fc&#x003B3; R-mediated phagocytosis, regulation of actin cytoskeleton, vascular endothelial growth factor (VEGF) signaling pathway, B cell receptor signaling pathway and T cell receptor signaling pathway (<xref rid="tIII-mmr-07-05-1417" ref-type="table">Table III</xref>).</p></sec>
<sec>
<title>qRT-PCR validation of differential genes in the microarrays</title>
<p>A subset of 3 genes, Mapk3, Pak1 and Rac2, that reveal differential methylation between the control and ALI/ARDS groups were validated using qRT-PCR to confirm the microarray results independently. Mapk3 and Pak1 showed DNA methylation in the control group. However, in the ALI/ARDS group, Rac2 was methylated. A close correlation was observed between the microarray and qRT-PCR data (<xref rid="tIV-mmr-07-05-1417" ref-type="table">Table IV</xref>), indicating the accuracy of our microarray data and the significant induction in the expression of candidate genes following LPS.</p></sec></sec>
<sec sec-type="discussion">
<title>Discussion</title>
<p>The present study reports, to the best of our knowledge, the first genome-wide DNA methylation analysis of rat lung tissues with LPS-induced ALI/ARDS. A genome-wide DNA methylation analysis of lung tissues with ALI/ARDS was performed in rats. In addition, the promoter regions of 1,721 genes and the CpG islands of 990 genes were found to exhibit aberrant levels of DNA methylation compared with normal lung tissues. Next, the DNA methylation status of three candidate genes, Mapk3, Pak1 and Rac2, was validated using qRT-PCR. The chromosomal locations of these genes were identified and chromosomes 1, 3, 5, 7 and 10 were identified to be the most common locations of these genes. Specific genes on these chromosomes, including Mapk3 (<xref rid="b16-mmr-07-05-1417" ref-type="bibr">16</xref>) and Lat (<xref rid="b17-mmr-07-05-1417" ref-type="bibr">17</xref>) on chromosome 1, Mylk2 and Cebpb (<xref rid="b17-mmr-07-05-1417" ref-type="bibr">17</xref>) on chromosome 3, Rac2 (<xref rid="b18-mmr-07-05-1417" ref-type="bibr">18</xref>) on chromosome 7 and Ace (<xref rid="b19-mmr-07-05-1417" ref-type="bibr">19</xref>) on chromosome 10, have been reported to be critical factors in the development of ALI/ARDS. Therefore, aberrant DNA methylation on chromosomes 1, 3, 5, 7 and 10 may be associated with the pathogenesis of ALI/ARDS.</p>
<p>In the current study, the differences in DNA methylation patterns for 3 classes of CpG island, HCP, ICP and LCP, were observed. Among the CpG island distribution categories, a number of genes in HCP may be associated with housekeeping genes and regulate developmental genes, whereas genes in LCP are largely associated with tissue-specific genes (<xref rid="b20-mmr-07-05-1417" ref-type="bibr">20</xref>), which indicates that, based on CpG density, analyzing methylation changes may provide additional insight. DNA methylation levels differed significantly among the 3 categories. The 1,721 genes methylated in the promoter region include 452 genes with a decreased degree of methylation and 1,269 genes with an increased degree of methylation. The incidence of methylated HCP genes in the decreased group was higher (n&#x0003D;223, P&lt;0.01). However, in the increased group, the incidence of methylated genes in the three categories was not found to be significant. A similar distribution was observed in the genes methylated in the CpG island: methylated HCP genes in the decreased and increased groups were markedly higher (P&lt;0.01). Results indicate that a higher number of housekeeping and developmental genes are regulated than tissue-specific genes in the pathophysiology of ALI/ARDS. Overall, the observations of the current study demonstrated that DNA methylation is associated with CpG density, DNA methylation has a higher incidence in HCP genes compared with ICP and LCP genes and housekeeping and developmental genes may play crucial roles in the pathophysiology of LPS-induced ALI/ARDS.</p>
<p>From our methylated genes, which were association studies with positive findings in ALI/ARDS, we identified 14 methylated genes. Among these genes, a substantial number have been demonstrated to play a functional role in LPS-induced ALI/ARDS. Of the 14 methylated genes, angiotensin-converting enzyme (ACE), is the key enzyme that converts AT-I to AT-II and its functions are involved in the positive regulation of apoptotic process, angiotensin signaling process, the renin-angiotensin cascade pathway and angiotensin II signaling pathway. ACE I/D polymorphism affects the prognosis of ALI/ARDS (<xref rid="b21-mmr-07-05-1417" ref-type="bibr">21</xref>). ALI/ARDS is characterized by alveolar injury and increased pulmonary vascular permeability. Mura <italic>et al</italic>(<xref rid="b22-mmr-07-05-1417" ref-type="bibr">22</xref>) reported a potential role for VEGF in promoting the repair of the alveolar-capillary membrane during recovery from ALI/ARDS. Vegfb is associated with the VEGF signaling pathway and is involved in the promotion of angiogenesis. The methylation of Vegfb may affect repair of the alveolar-capillary membrane and angiogenesis.</p>
<p>One of the principal mechanisms of LPS-induced ALI/ARDS relates to the effects of the inflammatory response, which leads to SIRS, including activation of leukocytes-alveolar macrophages and sequestered neutrophils in the lungs. A previous genetic study on ALI/ARDS reported that genes associated with the inflammatory response are important in the development of ALI/ARDS. The present study found that following genes associated with the inflammatory response exhibited aberrant DNA methylation profiles: i) Cebpb, CCAAT/enhancer-binding protein &#x003B2;, is a critical regulator of the inflammatory responses and injury in the lungs (<xref rid="b23-mmr-07-05-1417" ref-type="bibr">23</xref>); ii) Cxcl2 is a potent neutrophil chemokine involved in the pulmonary inflammatory response, which is linked to ventilator-induced ALI and hyperoxia-induced ALI. Inhibition of its receptor leads to a marked decrease in neutrophil sequestration and lung injury (<xref rid="b24-mmr-07-05-1417" ref-type="bibr">24</xref>); iii) IL6 is a potent proinflammatory cytokine and key factor in the development of ALI/ARDS (<xref rid="b25-mmr-07-05-1417" ref-type="bibr">25</xref>); iv) Mylk2 encodes proteins involved in multiple components of the inflammatory response, including apoptosis, vascular permeability and leukocyte diapedesis. Myosin light-chain kinase, a central cytoskeletal regulator encoded by Mylk, has a key pathophysiological role in ALI (<xref rid="b26-mmr-07-05-1417" ref-type="bibr">26</xref>); and v) Mif, macrophage migration inhibitory factor, is involved in the pathogenesis of several inflammatory diseases. Mif-induced neutrophils accumulate in the alveolar space, indicating that Mif may be a useful target in the reduction of neutrophil lung inflammation and ALI (<xref rid="b27-mmr-07-05-1417" ref-type="bibr">27</xref>). These methylated genes are involved in important mechanisms that underlie ALI/ARDS. However, further studies are required to identify the correlation between the aberrant methylation of these genes and the pathogenesis of LPS-induced ALI/ARDS.</p>
<p>According to KEGG pathway analysis, 10 enrichment pathways were selected. Of the top 10 enrichment pathways, MAPK is an important signal transmitter from the cell surface to the internal nucleus and is mainly involved in cell differentiation and proliferation, apoptosis and regulation of immune and inflammatory responses. MAPK initiates a cascade of inflammatory cytokines, leading to an uncontrolled inflammatory response. LPS induces an inflammatory reaction through the activation of the MAPK signaling pathway. Thus, the MAPK signaling pathway may have an essential role in the development of pulmonary inflammation and LPS-induced ALI/ARDS. A total of 42 methylated genes are associated with the MAPK signaling pathway and 7 have been associated with ALI/ARDS in previous studies, including Akt2 (<xref rid="b28-mmr-07-05-1417" ref-type="bibr">28</xref>), Casp3 (<xref rid="b29-mmr-07-05-1417" ref-type="bibr">29</xref>), Mapk3 (<xref rid="b16-mmr-07-05-1417" ref-type="bibr">16</xref>), Pak1 (<xref rid="b30-mmr-07-05-1417" ref-type="bibr">30</xref>), Rac2 (<xref rid="b18-mmr-07-05-1417" ref-type="bibr">18</xref>), Tgfb1 and Tgfb2 (<xref rid="b31-mmr-07-05-1417" ref-type="bibr">31</xref>). These genes have a functional role in the MAPK signaling pathway and aberrant methylation of these genes may affect its activation and inflammatory response in LPS-induced ALI/ARDS.</p>
<p>In summary, the Roche-NimbleGen Rat DNA methylation 385K CpG islands plus promoter array is a useful tool for studying the genome-wide DNA methylation of lung tissues with LPS-induced ALI/ARDS. Aberrant DNA methylation in ALI/ARDS was determined and altered patterns of lung DNA methylation during the pathophysiology of LPS-induced ALI/ARDS were observed. The identification of a lung gene-specific methylation profile may provide valuable insight into pathways that are likely to be epigenetically regulated. Further analysis of DNA methylation is important for the understanding of ALI/ARDS and may be of value for indicating prognostic biomarkers and predictors of response to therapy and may constitute future therapeutic targets.</p></sec></body>
<back>
<ack>
<title>Acknowledgements</title>
<p>This study was supported by grants from the Natural Science Foundation of Shandong Province, China (Y2008C163). The authors thank Kangchen Biotech Company for assistance with the analyses.</p></ack>
<glossary>
<title>Abbreviations</title>
<def-list>
<def-item>
<term id="G1">LPS</term>
<def>
<p>lipopolysaccharide</p></def></def-item>
<def-item>
<term id="G2">ALI</term>
<def>
<p>acute lung injury</p></def></def-item>
<def-item>
<term id="G3">ARDS</term>
<def>
<p>acute respiratory distress syndrome</p></def></def-item>
<def-item>
<term id="G4">PBS</term>
<def>
<p>phosphate-buffered saline</p></def></def-item>
<def-item>
<term id="G5">HCP</term>
<def>
<p>high density CpG promoters</p></def></def-item>
<def-item>
<term id="G6">LCP</term>
<def>
<p>low density CpG promoters</p></def></def-item>
<def-item>
<term id="G7">ICP</term>
<def>
<p>intermediate density CpG promoters</p></def></def-item>
<def-item>
<term id="G8">MeDIP</term>
<def>
<p>methylated DNA immunoprecipitation</p></def></def-item>
<def-item>
<term id="G9">GO</term>
<def>
<p>gene ontology</p></def></def-item>
<def-item>
<term id="G10">KEGG</term>
<def>
<p>Kyoto Encyclopedia of Genes and Genomes</p></def></def-item></def-list></glossary>
<ref-list>
<title>References</title>
<ref id="b1-mmr-07-05-1417"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rubenfeld</surname><given-names>GD</given-names></name><name><surname>Caldwell</surname><given-names>E</given-names></name><name><surname>Peabody</surname><given-names>E</given-names></name><etal/></person-group><article-title>Incidence and outcomes of acute lung injury</article-title><source>N Engl J Med</source><volume>353</volume><fpage>1685</fpage><lpage>1693</lpage><year>2005</year></element-citation></ref>
<ref id="b2-mmr-07-05-1417"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zambon</surname><given-names>M</given-names></name><name><surname>Vincent</surname><given-names>JL</given-names></name></person-group><article-title>Mortality rates for patients with acute lung injury/ARDS have decreased over time</article-title><source>Chest</source><volume>133</volume><fpage>1120</fpage><lpage>1127</lpage><year>2008</year></element-citation></ref>
<ref id="b3-mmr-07-05-1417"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>HM</given-names></name><name><surname>Bodenstein</surname><given-names>M</given-names></name><name><surname>Markstaller</surname><given-names>K</given-names></name></person-group><article-title>Overview of the patolgy of three widely used animal models of acute lung injury</article-title><source>Eur Surg Res</source><volume>40</volume><fpage>305</fpage><lpage>316</lpage><year>2008</year></element-citation></ref>
<ref id="b4-mmr-07-05-1417"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>El Gazzar</surname><given-names>M</given-names></name><name><surname>Yoza</surname><given-names>BK</given-names></name><name><surname>Hu</surname><given-names>JY</given-names></name><name><surname>Cousart</surname><given-names>SL</given-names></name><name><surname>McCall</surname><given-names>CE</given-names></name></person-group><article-title>Epigenetic silencing of tumor necrosis factor alpha during endotoxin tolerance</article-title><source>J Biol Chem</source><volume>282</volume><fpage>26857</fpage><lpage>26864</lpage><year>2007</year></element-citation></ref>
<ref id="b5-mmr-07-05-1417"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Angrisano</surname><given-names>T</given-names></name><name><surname>Pero</surname><given-names>R</given-names></name><name><surname>Peluso</surname><given-names>S</given-names></name><etal/></person-group><article-title>LPS-induced IL-8 activation in human intestinal epithelial cells is accompanied by specific histone H3 acetylation and methylation changes</article-title><source>BMC Microbiol</source><volume>10</volume><fpage>172</fpage><year>2010</year></element-citation></ref>
<ref id="b6-mmr-07-05-1417"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tatemichi</surname><given-names>M</given-names></name><name><surname>Hata</surname><given-names>H</given-names></name><name><surname>Tazawa</surname><given-names>H</given-names></name><name><surname>Nakadate</surname><given-names>T</given-names></name></person-group><article-title>Lipopolysaccharide induces aberrant hypermethylation of Hic-1 in mouse embryonic fibroblasts lacking p53</article-title><source>Anticancer Res</source><volume>28</volume><fpage>2101</fpage><lpage>2108</lpage><year>2008</year></element-citation></ref>
<ref id="b7-mmr-07-05-1417"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kiefer</surname><given-names>JC</given-names></name></person-group><article-title>Epigenetics in development</article-title><source>Dev Dyn</source><volume>236</volume><fpage>1144</fpage><lpage>1156</lpage><year>2007</year></element-citation></ref>
<ref id="b8-mmr-07-05-1417"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Holliday</surname><given-names>R</given-names></name><name><surname>Pugh</surname><given-names>JE</given-names></name></person-group><article-title>DNA modification mechanisms and gene activity during development</article-title><source>Science</source><volume>187</volume><fpage>226</fpage><lpage>232</lpage><year>1975</year></element-citation></ref>
<ref id="b9-mmr-07-05-1417"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leonhardt</surname><given-names>H</given-names></name><name><surname>Bestor</surname><given-names>TH</given-names></name></person-group><article-title>Structure, function and regulation of mammalian DNA methyltransferase</article-title><source>EXS</source><volume>64</volume><fpage>109</fpage><lpage>119</lpage><year>1993</year></element-citation></ref>
<ref id="b10-mmr-07-05-1417"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Klose</surname><given-names>RJ</given-names></name><name><surname>Bird</surname><given-names>AP</given-names></name></person-group><article-title>Genomic DNA methylation: the mark and its mediators</article-title><source>Trends Biochem Sci</source><volume>31</volume><fpage>89</fpage><lpage>97</lpage><year>2006</year></element-citation></ref>
<ref id="b11-mmr-07-05-1417"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heller</surname><given-names>G</given-names></name><name><surname>Zielinski</surname><given-names>CC</given-names></name><name><surname>Z&#x000F6;chbauer-M&#x000FC;ller</surname><given-names>S</given-names></name></person-group><article-title>Lung cancer: from single-gene methylation to methylome profiling</article-title><source>Cancer Metastasis Rev</source><volume>29</volume><fpage>95</fpage><lpage>107</lpage><year>2010</year></element-citation></ref>
<ref id="b12-mmr-07-05-1417"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adcock</surname><given-names>IM</given-names></name><name><surname>Tsaprouni</surname><given-names>L</given-names></name><name><surname>Bhavsar</surname><given-names>P</given-names></name><name><surname>Ito</surname><given-names>K</given-names></name></person-group><article-title>Epigenetic regulation of airway inflammation</article-title><source>Curr Opin Immunol</source><volume>19</volume><fpage>694</fpage><lpage>700</lpage><year>2007</year></element-citation></ref>
<ref id="b13-mmr-07-05-1417"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boellmann</surname><given-names>F</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Clewell</surname><given-names>HJ</given-names></name><name><surname>Schroth</surname><given-names>GP</given-names></name><name><surname>Kenyon</surname><given-names>EM</given-names></name><name><surname>Andersen</surname><given-names>ME</given-names></name><name><surname>Thomas</surname><given-names>RS</given-names></name></person-group><article-title>Genome-wide analysis of DNA methylation and gene expression changes in the mouse lung following subchronic arsenate exposure</article-title><source>Toxicol Sci</source><volume>117</volume><fpage>404</fpage><lpage>417</lpage><year>2010</year></element-citation></ref>
<ref id="b14-mmr-07-05-1417"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jia</surname><given-names>RZ</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>HU</surname><given-names>P</given-names></name><name><surname>Liu</surname><given-names>XM</given-names></name><name><surname>Hua</surname><given-names>XD</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Ding</surname><given-names>HJ</given-names></name></person-group><article-title>Screening for differential methylation status in human placenta in preeclampsia using a CpG island plus promoter microarray</article-title><source>Int J Mol Med</source><volume>30</volume><fpage>133</fpage><lpage>141</lpage><year>2012</year></element-citation></ref>
<ref id="b15-mmr-07-05-1417"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Flores</surname><given-names>C</given-names></name><name><surname>Pino-Yanes</surname><given-names>MM</given-names></name><name><surname>Villar</surname><given-names>J</given-names></name></person-group><article-title>A quality assessment of genetic association studies supporting susceptibility and outcome in acute lung injury</article-title><source>Crit Care</source><volume>12</volume><fpage>R130</fpage><year>2008</year></element-citation></ref>
<ref id="b16-mmr-07-05-1417"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Di Paola</surname><given-names>R</given-names></name><name><surname>Cisafulli</surname><given-names>C</given-names></name><name><surname>Mazzon</surname><given-names>E</given-names></name><name><surname>Genovese</surname><given-names>T</given-names></name><name><surname>Paterniti</surname><given-names>I</given-names></name><name><surname>Bramanti</surname><given-names>P</given-names></name><name><surname>Cuzzocrea</surname><given-names>S</given-names></name></person-group><article-title>Effect of PD98059, a selective MAPK3/MAPK1 inhibitor, on acute lung injury in mice</article-title><source>Int J Immunopathol Pharmacol</source><volume>22</volume><fpage>937</fpage><lpage>950</lpage><year>2009</year></element-citation></ref>
<ref id="b17-mmr-07-05-1417"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grigoryev</surname><given-names>DN</given-names></name><name><surname>Finigan</surname><given-names>JH</given-names></name><name><surname>Hassoun</surname><given-names>P</given-names></name><name><surname>Garcia</surname><given-names>JG</given-names></name></person-group><article-title>Science review: searching for gene candidates in acute lung injury</article-title><source>Crit Care</source><volume>8</volume><fpage>440</fpage><lpage>447</lpage><year>2004</year></element-citation></ref>
<ref id="b18-mmr-07-05-1417"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yao</surname><given-names>HY</given-names></name><name><surname>Chen</surname><given-names>L</given-names></name><name><surname>Xu</surname><given-names>C</given-names></name></person-group><article-title>Inhibition of Rac activity alleviates lipopolysaccharide-induced acute pulmonary injury in mice</article-title><source>Biochim Biophys Acta</source><volume>1810</volume><fpage>666</fpage><lpage>674</lpage><year>2011</year></element-citation></ref>
<ref id="b19-mmr-07-05-1417"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Flores</surname><given-names>C</given-names></name><name><surname>Pino-Yanes</surname><given-names>MM</given-names></name><name><surname>Casula</surname><given-names>M</given-names></name><name><surname>Casula</surname><given-names>M</given-names></name><name><surname>Villar</surname><given-names>J</given-names></name></person-group><article-title>Genetics of acute lung injury: past, present and future</article-title><source>Minerva Anestesiol</source><volume>76</volume><fpage>860</fpage><lpage>864</lpage><year>2010</year></element-citation></ref>
<ref id="b20-mmr-07-05-1417"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saxonov</surname><given-names>S</given-names></name><name><surname>Berg</surname><given-names>P</given-names></name><name><surname>Brutlag</surname><given-names>DL</given-names></name></person-group><article-title>A genome-wide analysis of CpG dinucleotides in the human genome distinguishes two distinct classes of promoters</article-title><source>Proc Natl Acad Sci USA</source><volume>103</volume><fpage>1412</fpage><lpage>1417</lpage><year>2006</year></element-citation></ref>
<ref id="b21-mmr-07-05-1417"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adamzik</surname><given-names>M</given-names></name><name><surname>Frey</surname><given-names>U</given-names></name><name><surname>Sixt</surname><given-names>S</given-names></name><name><surname>Knemeyer</surname><given-names>L</given-names></name><name><surname>Beiderlinden</surname><given-names>M</given-names></name><name><surname>Peters</surname><given-names>J</given-names></name><name><surname>Siffert</surname><given-names>W</given-names></name></person-group><article-title>ACE I/D but not AGT (-6)A/G polymorphism is a risk factor for mortality in ARDS</article-title><source>Eur Respir J</source><volume>29</volume><fpage>482</fpage><lpage>488</lpage><year>2007</year></element-citation></ref>
<ref id="b22-mmr-07-05-1417"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mura</surname><given-names>M</given-names></name><name><surname>dos Santos</surname><given-names>CC</given-names></name><name><surname>Stewart</surname><given-names>D</given-names></name><name><surname>Liu</surname><given-names>M</given-names></name></person-group><article-title>Vascular endothelial growth factor and related molecules in acute lung injury</article-title><source>J Appl Physiol</source><volume>97</volume><fpage>1605</fpage><lpage>1617</lpage><year>2004</year></element-citation></ref>
<ref id="b23-mmr-07-05-1417"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yan</surname><given-names>C</given-names></name><name><surname>Wu</surname><given-names>M</given-names></name><name><surname>Cao</surname><given-names>J</given-names></name><name><surname>Tang</surname><given-names>H</given-names></name><name><surname>Zhu</surname><given-names>M</given-names></name><name><surname>Johnson</surname><given-names>PF</given-names></name><name><surname>Gao</surname><given-names>H</given-names></name></person-group><article-title>Critical role for CCAAT/enhancer-binding protein &#x003B2; in immune complex-induced acute lung injury</article-title><source>J Immunol</source><volume>189</volume><fpage>1480</fpage><lpage>1490</lpage><year>2012</year></element-citation></ref>
<ref id="b24-mmr-07-05-1417"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Belperio</surname><given-names>JA</given-names></name><name><surname>Keane</surname><given-names>MP</given-names></name><name><surname>Burdick</surname><given-names>MD</given-names></name><etal/></person-group><article-title>Critical role for CXCR2 and CXCR2 ligands during the pathogenesis of ventilator-induced lung injury</article-title><source>J Clin Invest</source><volume>110</volume><fpage>1703</fpage><lpage>1716</lpage><year>2002</year></element-citation></ref>
<ref id="b25-mmr-07-05-1417"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Flores</surname><given-names>C</given-names></name><name><surname>Ma</surname><given-names>SF</given-names></name><name><surname>Maresso</surname><given-names>K</given-names></name><name><surname>Wade</surname><given-names>MS</given-names></name><name><surname>Villar</surname><given-names>J</given-names></name><name><surname>Garcia</surname><given-names>JG</given-names></name></person-group><article-title>IL-6 gene-wide haplotype is association with susceptibility to acute lung injury</article-title><source>Transl Res</source><volume>152</volume><fpage>11</fpage><lpage>17</lpage><year>2008</year></element-citation></ref>
<ref id="b26-mmr-07-05-1417"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Han</surname><given-names>YJ</given-names></name><name><surname>Ma</surname><given-names>SF</given-names></name><name><surname>Wade</surname><given-names>MS</given-names></name><name><surname>Flores</surname><given-names>C</given-names></name><name><surname>Garcia</surname><given-names>JG</given-names></name></person-group><article-title>An intronic MYLK variant associated with inflammatory lung disease regulates promoter activity of the smooth muscle myosin light chain kinase isoform</article-title><source>J Mol (Berl)</source><volume>90</volume><fpage>299</fpage><lpage>308</lpage><year>2012</year></element-citation></ref>
<ref id="b27-mmr-07-05-1417"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takahashi</surname><given-names>K</given-names></name><name><surname>Koga</surname><given-names>K</given-names></name><name><surname>Linge</surname><given-names>HM</given-names></name><etal/></person-group><article-title>Macrophage CD74 contributes to MIF-induced pulmonary inflammation</article-title><source>Respir Res</source><volume>10</volume><fpage>33</fpage><year>2009</year></element-citation></ref>
<ref id="b28-mmr-07-05-1417"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ikegami</surname><given-names>M</given-names></name><name><surname>Falcone</surname><given-names>A</given-names></name><name><surname>Whitsett</surname><given-names>JA</given-names></name></person-group><article-title>STAT-3 regulates surfactant phospholipid homeostasis in normal lung and during endotoxin-mediated lung injury</article-title><source>J Appl Physiol</source><volume>104</volume><fpage>1753</fpage><lpage>1760</lpage><year>2008</year></element-citation></ref>
<ref id="b29-mmr-07-05-1417"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perl</surname><given-names>M</given-names></name><name><surname>Chung</surname><given-names>CS</given-names></name><name><surname>Perl</surname><given-names>U</given-names></name><name><surname>Thakkar</surname><given-names>R</given-names></name><name><surname>Lomas-Neira</surname><given-names>J</given-names></name><name><surname>Ayala</surname><given-names>A</given-names></name></person-group><article-title>Therapeutic accessibility of caspase-mediated cell death as a key pathomechanism in indirect acute lung injury</article-title><source>Crit Care Med</source><volume>38</volume><fpage>1179</fpage><lpage>1186</lpage><year>2010</year></element-citation></ref>
<ref id="b30-mmr-07-05-1417"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Birukova</surname><given-names>AA</given-names></name><name><surname>Xing</surname><given-names>J</given-names></name><name><surname>Fu</surname><given-names>P</given-names></name><etal/></person-group><article-title>Atrial natriuretic peptide attenuates LPS-induced vascular leak: role of PAK1</article-title><source>Am J Physiol Lung Cell Mol Physiol</source><volume>299</volume><fpage>L652</fpage><lpage>L663</lpage><year>2010</year></element-citation></ref>
<ref id="b31-mmr-07-05-1417"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leite-Junior</surname><given-names>JH</given-names></name><name><surname>Garcia</surname><given-names>CS</given-names></name><name><surname>Souza-Fernandes</surname><given-names>AB</given-names></name><etal/></person-group><article-title>Methylprednisolone improves lung mechanics and reduces the inflammatory response in pulmonary but not in extrapulmonary mild acute lung injury in mice</article-title><source>Crit Care Med</source><volume>36</volume><fpage>2621</fpage><lpage>2628</lpage><year>2008</year></element-citation></ref></ref-list></back>
<floats-group>
<fig id="f1-mmr-07-05-1417" position="float">
<label>Figure 1</label>
<caption>
<p>Pulmonary histopathological changes in LPS-administered rats. Lung tissue specimens were obtained from the control group, magnification (A) &#x000D7;100 and (B) &#x000D7;400; and LPS group, magnification (C) &#x000D7;100 and (D) &#x000D7;400. LPS, lipopolysaccharide.</p></caption>
<graphic xlink:href="MMR-07-05-1417-g00.gif"/></fig>
<fig id="f2-mmr-07-05-1417" position="float">
<label>Figure 2</label>
<caption>
<p>Number of genes methylated in the promoter and CpG island. (A) A total of 1,721 candidate genes in the promoter were distributed across all chromosomes. (B) 990 candidate genes in the CpG island were distributed across all chromosomes.</p></caption>
<graphic xlink:href="MMR-07-05-1417-g01.gif"/></fig>
<fig id="f3-mmr-07-05-1417" position="float">
<label>Figure 3</label>
<caption>
<p>Levels of DNA methylation in the promoter and CpG island. Methylation level and the CpG density in the (A) promoter and (B) CpG island. HCP, high CpG density promoter; ICP, intermediate CpG density promoter; LCP, low CpG density promoter.</p></caption>
<graphic xlink:href="MMR-07-05-1417-g02.gif"/></fig>
<table-wrap id="tI-mmr-07-05-1417" position="float">
<label>Table I</label>
<caption>
<p>GO annotation of the candidate genes identified by microarray. Methylated genes involved in the response to external stimulus, intracellular signal transduction and negative regulation of cell proliferation.</p></caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" valign="top">GO term</th>
<th align="center" valign="top">Focus genes</th>
<th align="center" valign="top">Gene name</th></tr></thead>
<tbody>
<tr>
<td align="left" valign="top">Intracellular signal transduction</td>
<td align="center" valign="top">205</td>
<td align="left" valign="top">ADRA2B//PAK1//MAPK3//MAP2K2//TGFB1//MAPK12//RGD1562846//CDKN1A//<break/>FOXM1//HTR6//PTGER3//GCGR//CNR1//GNAZ//MC3R//GHRH//AVPR1B//<break/>GLP2R//PTHLH//GNAS//ADRB1//ADORA2A//GALR1//ADCY5//DRD3//NPR3//<break/>INSL3//GRM7//GRIK3//FZD1//NMUR1//CASR//ATP2B4//LAT//RCAN2//ALMS1//<break/>RCAN3//SIK1//MARK2//SOCS3//MAP4K2//SRPK2//STK4//RPS6KA5//MAST1//<break/>CARD9//CSNK2B//SNIP1//AZI2//RIPK2//AGT//ERC1//TRIB1//ROR2//STRADB//<break/>DAB2IP//WNT7B//GAB1//MAPK8IP1//GH1//F2R//MRAS//RAB4B//ARL3//<break/>RAB6A//RHOQ//ARHGEF7//RALB//ARFRP1//RAB35//ARL9//RAB40B//<break/>RHOBTB1//RASL12//RAB40C//DNAJA3//RGD1307615//REM1//DIRAS1//RAC2//<break/>RAB20//RAB1B//GRB2//SYNGAP1//RASSF1//RSU1//CDC42EP1//ARHGDIA//<break/>XPA//PDE4D//MIF//FGF1//PIK3R1//PLEKHA1//LIME1//RELN//TGFB2//PTPN6//<break/>GPER//UBE3A//TBXA2R//PDE7A//IGFBP1//FOXO3//RPS6KB1//EIF4EBP1//<break/>DISC1//HIF1A//AKT1S1//TMEM127//CYTH1//IQSEC3//CYTH4//GSTP1//CRHR2//<break/>TAOK1//STMN3//ARHGEF15//ARHGEF3//FARP1//PLEKHG4//RGNEF//NGFR//<break/>LPAR1//LPAR2//SOX11//PTK6//IL6//IL3//PHLDA3//PDPK1//NUP62//SLC20A1//<break/>ATP2C1//TRADD//CXXC5//UBE2V1//LTBR//MAVS//NEK6//GOLT1B//MYLK2//<break/>P2RX7//PTPRC//INSR//FGFR2//LPAR3//FGFR1//FLT4//IGFBP4//AKT2//RPS6KB2//<break/>MAP3K10//FZD5//LOC682999//SNAI1//CDC34//MECOM//SERPINF2//CD27//<break/>LEPROT//RASA2//TNK1//CMKLR1//ADA//VEGFB//F7//TCF7L2//CCL11//DUSP6//<break/>NDRG2//FGF21//ARHGAP8//MYBBP1A//CASP3//RGS7//ECEL1//UNC13A//<break/>PDZD2//GUCY2E//SMAD7//CSPG4//PSEN2//DUSP1//PBP2//PLCL2//SPSB3//<break/>ADCY1//PDZD8//ARHGAP29//HMHA1//PLCZ1//ASB10//SOCS5</td></tr>
<tr>
<td align="left" valign="top">Negative regulation of cell proliferation</td>
<td align="center" valign="top">65</td>
<td align="left" valign="top">SULF1//KRIT1//TGFB1//ASCL2//CASP3//DLG1//SCGB1A1//PTPN6//GSTP1//LTA//<break/>DAB2IP//APOD//PIK3R1//TRIB1//SF1//NDRG2//ANG1//GAL//LST1//SOX11//<break/>FGFR2//GPC3//TGFB2//PTCH1//RUNX3//LRP6//KRT4//PAK1//TSPO//GATA2//<break/>WT1//AGT//CEBPA//IL6//JUN//NOS1//FOXA3//BDKRB2//PHB//ADORA2A//F2R//<break/>PPARG//BMP2//WISP2//PTGES//NUP62//GABBR1//INSL3//BECN1//CDKN1A//<break/>ALDH1A2//PTPRU//TFF1//SOX7//ENPP7//ROR2//CDH5//TMEM127//STK4//<break/>FZD5//PTPRF//DNAJA3//IRF6//LEFTY1//KLF13</td></tr>
<tr>
<td align="left" valign="top">Response to external stimulus</td>
<td align="center" valign="top">146</td>
<td align="left" valign="top">BECN1//WIPI2//MAP1LC3A//ATG9A//CLN3//TRPM4//CCL11//PPARG//IL6//<break/>ALOX5AP//MIF//F7//CNR1//LTA//CMKLR1//CXCL2//S100A8//CCR10//RAC2//<break/>JUN//JUND//RELN//MGP//ACCN1//KCNA5//BMP2//HIF1A//P2RX7//CTSB//<break/>RPS6KB1//PTCH1//ACCN3//NGFR//NKX2-1//PLA2G10//APBB1//SEMA6C//<break/>SEMA3A//MYH10//TGFB2//EFNA2//NFASC//RUNX3//GDF7//EPHB3//PGRMC1//<break/>KLF7//NRCAM//CEBPA//TBXA2R//PIK3R1//COX4I1//DDIT3//PLEC//CHAT//<break/>SLC6A19//OPN4//TULP1//PDE6C//HOXA2//FOXA3//CARTPT//GAS2L1//PDE6B//<break/>GRK1//TSPO//RARRES2//FOXG1//AGT//MAPK3//BAD//CYBA//BNIP3//LTBR//<break/>HABP4//F2R//CR1L//ZIC2//ACE//GSTP1//LIPC//NOS1//INSR//SDS//TH//AKT2//<break/>THRA//SLC1A2//CDKN1A//PRDM4//G6PD//GH1//CLPS//GHRH//GHSR//SOCS3//<break/>PNLIPRP2//SLC22A3//IGF2R//PTGES//SCAMP3//RPL36AL//DUSP1//DKK1//<break/>CLK2//LEFTY1//PITX2//ALDH1A2//ADA//ORM1//HMGCS1//ALPL//TGFB1//<break/>TRIM25//EGR3//MYBBP1A//PFKFB1//AK3//ACADS//SSTR3//AANAT//DSCAM//<break/>FOXE1//SCGB1A1//SETD6//ADORA2A//CNR2//HSPD1//DRD3//ATP2B2//CDH23//<break/>FGF7//VEGFB//ZFP354A//LRP6//SERPINF2//LTC4S//PTK7//WNT7B//RXRB//<break/>PTK6//FZD1//SKP2//LPAR1//MECOM//RPS6KA5</td></tr></tbody></table></table-wrap>
<table-wrap id="tII-mmr-07-05-1417" position="float">
<label>Table II</label>
<caption>
<p>Methylated gene association studies in acute lung injury and acute respiratory distress syndrome (ALI/ARDS).</p></caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" valign="top">Gene symbol</th>
<th align="center" valign="top">Protein name</th>
<th align="center" valign="top">Description</th></tr></thead>
<tbody>
<tr>
<td align="left" valign="top">Ace</td>
<td align="left" valign="top">Angiotensin-converting enzyme</td>
<td align="left" valign="top">Catalyzes the conversion of angiotensin I to angiotensin; plays a role in regulation of blood pressure.</td></tr>
<tr>
<td align="left" valign="top">Akt2</td>
<td align="left" valign="top">RAC-&#x003B2; serine/threonine protein kinase</td>
<td align="left" valign="top">Involved in phosphatidylinositol 3-kinase-mediated signaling.</td></tr>
<tr>
<td align="left" valign="top">Casp3</td>
<td align="left" valign="top">Caspase-3</td>
<td align="left" valign="top">Apoptotic cysteine-aspartic acid protease that may play a role in neuronal cell death regulation and other apoptotic processes.</td></tr>
<tr>
<td align="left" valign="top">Cebpb</td>
<td align="left" valign="top">CCAAT/enhancer-binding protein &#x003B2;</td>
<td align="left" valign="top">Transcription factor that binds to CCAAT motif on DNA and may facilitate IL-6 induced transcriptional activation.</td></tr>
<tr>
<td align="left" valign="top">Cxcl2</td>
<td align="left" valign="top">C-X-C motif chemokine 2</td>
<td align="left" valign="top">Chemokine involved in the pulmonary inflammatory response.</td></tr>
<tr>
<td align="left" valign="top">IL6</td>
<td align="left" valign="top">Interleukin-6</td>
<td align="left" valign="top">Cytokine involved in development and possibly in neurodegenerative processes.</td></tr>
<tr>
<td align="left" valign="top">Mapk3</td>
<td align="left" valign="top">Mitogen-activated protein kinase 3</td>
<td align="left" valign="top">Kinase involved in intracellular signalling; component of MAPK signaling pathway.</td></tr>
<tr>
<td align="left" valign="top">Mif</td>
<td align="left" valign="top">Macrophage migration inhibitory factor</td>
<td align="left" valign="top">Inhibits random migration of macrophages and is involved in the pathogenesis of several inflammatory diseases.</td></tr>
<tr>
<td align="left" valign="top">Mylk2</td>
<td align="left" valign="top">Myosin light chain kinase 2, skeletal/cardiac</td>
<td align="left" valign="top">Kinase; phosphorylates a serine in the N-terminus of a myosin light chain.</td></tr>
<tr>
<td align="left" valign="top">Pak1</td>
<td align="left" valign="top">Serine/threonine-protein kinase PAK 1</td>
<td align="left" valign="top">Serine/threonine protein kinase; binds and complexes specifically with activated (GTP-bound) p21, leading to inhibition of p21 GTPase activity.</td></tr>
<tr>
<td align="left" valign="top">Rac2</td>
<td align="left" valign="top">Ras-related C3 botulinum toxin substrate 2</td>
<td align="left" valign="top">Exhibits GTPAse activity, protein binding (homolog); involved in actin cytoskeleton organization and biogenesis, bone resorption; associated with neutrophil immunodeficiency syndrome.</td></tr>
<tr>
<td align="left" valign="top">Tgfb1</td>
<td align="left" valign="top">Transforming growth factor</td>
<td align="left" valign="top">Binds the TGF &#x003B2; receptor; plays a role in regulation of cell growth and &#x003B2;-1 proliferation; induces synthesis of extracellular matrix proteins and may play a role in fibrosis.</td></tr>
<tr>
<td align="left" valign="top">Tgfb2</td>
<td align="left" valign="top">Transforming growth factor &#x003B2;-2</td>
<td align="left" valign="top">Binds the transforming growth factor-&#x003B2; receptor; plays a role in regulation of cell growth and proliferation; may be involved in mesenchymal-epithelial cell interactions during development.</td></tr>
<tr>
<td align="left" valign="top">Vegfb</td>
<td align="left" valign="top">Vascular endothelial growth factor B</td>
<td align="left" valign="top">Mouse homolog is a growth factor; involved in the promotion of angiogenesis.</td></tr></tbody></table></table-wrap>
<table-wrap id="tIII-mmr-07-05-1417" position="float">
<label>Table III</label>
<caption>
<p>Pathway analysis of the candidate genes identified by microarray.</p></caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" valign="top">Signaling pathway</th>
<th align="center" valign="top">Focus genes</th>
<th align="center" valign="top">Gene name</th></tr></thead>
<tbody>
<tr>
<td align="left" valign="top">Neuroactive ligand receptor interaction</td>
<td align="center" valign="top">55</td>
<td align="left" valign="top">ADORA2A//ADRA1D//ADRA2B//ADRB1//APLNR//AVPR1B//BDKRB2//<break/>CHRM1//CHRM5//CHRNA4//CNR1//CNR2//CRHR2//DRD3//F2R//GABBR1//<break/>GABRA3//GABRG3//GABRR3//GALR1//GCGR//GH1//GHSR//GLP2R//<break/>GPR35//GRIA2//GRIK3//GRIK4//GRM7//HRH3//HTR1D//HTR6//LPAR1//<break/>LPAR2//LPAR3//MC3R//MC5R//NMUR1//NTSR1//P2RX7//P2RY14//PPYR1//<break/>PTGER3//PTGIR//SCTR//SSTR3//TAAR1//TAAR3//TAAR4//TAAR6//TAAR9//<break/>TBXA2R//THRA//TSPO//UTS2R</td></tr>
<tr>
<td align="left" valign="top">Neurotrophin signaling pathway</td>
<td align="center" valign="top">25</td>
<td align="left" valign="top">AKT2//AKT3//ARHGDIA//BAD//CALML3//CAMK2G//FOXO3//GAB1//<break/>GRB2//IRAK2//JUN//MAP2K2//MAPK12//MAPK3//NFKBIE//NGFR//NTF4//<break/>PIK3R1//PIK3R2//PRDM4//PSEN2//RIPK2//RPS6KA5//YWHAG//YWHAH</td></tr>
<tr>
<td align="left" valign="top">MAPK signaling pathway</td>
<td align="center" valign="top">42</td>
<td align="left" valign="top">AKT2//AKT3//CACNB2//CACNG1//CACNG5//CACNG6//CACNG8//CASP3//<break/>CHP2//DAXX//DDIT3//DUSP1//DUSP14//DUSP6//FGF1//FGF21//FGF7//<break/>FGFR1//FGFR2//GRB2//JUN//JUND//MAP2K2//MAP4K2//MAPK12//MAPK3//<break/>MAPK8IP1//MECOM//MRAS//NTF4//PAK1//PLA2G10//PLA2G2C//<break/>PLA2G2F//PPP3R2//RAC2//RASA2//RPS6KA5//STK4//TAOK1//TGFB1//<break/>TGFB2</td></tr>
<tr>
<td align="left" valign="top">Cholinergic synapse</td>
<td align="center" valign="top">21</td>
<td align="left" valign="top">ADCY1//ADCY5//AKT2//AKT3//CAMK2G//CHAT//CHRM1//CHRM5//<break/>CHRNA4//CREB3L3//GNB3//GNG7//GNG8//KCNJ2//KCNJ3//KCNJ4//<break/>KCNJ6//MAPK3//PIK3R1//PIK3R2//SLC18A3</td></tr>
<tr>
<td align="left" valign="top">mTOR signaling pathway</td>
<td align="center" valign="top">12</td>
<td align="left" valign="top">AKT2//AKT3//EIF4E//EIF4EBP1//HIF1A//MAPK3//PDPK1//PIK3R1//PIK3R2//<break/>RPS6KB1//RPS6KB2//VEGFB</td></tr>
<tr>
<td align="left" valign="top">Fc&#x003B3; R-mediated phagocytosis</td>
<td align="center" valign="top">19</td>
<td align="left" valign="top">AKT2//AKT3//AMPH//ARPC1B//ARPC2//ARPC4//DNM3//FCGR2A//LAT//<break/>LIMK1//MAPK3//PAK1//PIK3R1//PIK3R2//PIP5K1B//PTPRC//RAC2//<break/>RPS6KB1//RPS6KB2</td></tr>
<tr>
<td align="left" valign="top">Regulation of actin cytoskeleton</td>
<td align="center" valign="top">33</td>
<td align="left" valign="top">ACTB//APC2//ARHGEF7//ARPC1B//ARPC2//ARPC4//BDKRB2//CHRM1//<break/>CHRM5//F2R//FGD1//FGF1//FGF21//FGF7//FGFR1//FGFR2//ITGB4//LIMK1//<break/>MAP2K2//MAPK3//MRAS//MYH10//MYL7//MYLK2//NCKAP1//PAK1//<break/>PIK3R1//PIK3R2//PIP4K2B//PIP5K1B//PPP1CA//PPP1R12A//RAC2</td></tr>
<tr>
<td align="left" valign="top">VEGF signaling pathway</td>
<td align="center" valign="top">14</td>
<td align="left" valign="top">AKT2//AKT3//BAD//CHP2//MAP2K2//MAPK12//MAPK3//PIK3R1//PIK3R2//<break/>PLA2G10//PLA2G2C//PLA2G2F//PPP3R2//RAC2</td></tr>
<tr>
<td align="left" valign="top">B cell receptor signaling pathway</td>
<td align="center" valign="top">15</td>
<td align="left" valign="top">AKT2//AKT3//CHP2//DAPP1//GRB2//JUN//MAP2K2//MAPK3//NFKBIE//<break/>PIK3AP1//PIK3R1//PIK3R2//PPP3R2//PTPN6//RAC2</td></tr>
<tr>
<td align="left" valign="top">T cell receptor signaling pathway</td>
<td align="center" valign="top">18</td>
<td align="left" valign="top">AKT2//AKT3//CDK4//CHP2//DLG1//GRB2//JUN//LAT//MAP2K2//MAPK12//<break/>MAPK3//NFKBIE//PAK1//PIK3R1//PIK3R2//PPP3R2//PTPN6//PTPRC</td></tr></tbody></table></table-wrap>
<table-wrap id="tIV-mmr-07-05-1417" position="float">
<label>Table IV</label>
<caption>
<p>Gene methylation changes determined by quantitative reverse transcription-polymerase chain reaction.</p></caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" valign="top">Gene</th>
<th align="left" valign="top">Sample</th>
<th align="center" valign="top">Input (Ct)</th>
<th align="center" valign="top">IP (Ct)</th>
<th align="center" valign="top">&#x00025;</th></tr></thead>
<tbody>
<tr>
<td align="left" valign="top">Mapk3</td>
<td align="left" valign="top">Control</td>
<td align="center" valign="top">23.757</td>
<td align="center" valign="top">27.986</td>
<td align="center" valign="top">1.066</td></tr>
<tr>
<td align="left" valign="top"/>
<td align="left" valign="top">LPS</td>
<td align="center" valign="top">24.141</td>
<td align="center" valign="top">NA</td>
<td align="center" valign="top">NA</td></tr>
<tr>
<td align="left" valign="top">Pak1</td>
<td align="left" valign="top">Control</td>
<td align="center" valign="top">23.693</td>
<td align="center" valign="top">27.854</td>
<td align="center" valign="top">1.117</td></tr>
<tr>
<td align="left" valign="top"/>
<td align="left" valign="top">LPS</td>
<td align="center" valign="top">23.628</td>
<td align="center" valign="top">39.023</td>
<td align="center" valign="top">4.64E-04</td></tr>
<tr>
<td align="left" valign="top">Rac2</td>
<td align="left" valign="top">Control</td>
<td align="center" valign="top">20.783</td>
<td align="center" valign="top">36.298</td>
<td align="center" valign="top">4.27E-04</td></tr>
<tr>
<td align="left" valign="top"/>
<td align="left" valign="top">LPS</td>
<td align="center" valign="top">20.717</td>
<td align="center" valign="top">25.101</td>
<td align="center" valign="top">0.958</td></tr></tbody></table>
<table-wrap-foot><fn id="tfn1-mmr-07-05-1417">
<p>&#x00025; input &#x0003D; 2 &#x000D7; (Ct<sub>Input</sub> - Ct<sub>ChIP</sub>) &#x000D7; Fd &#x000D7; 100. Fd, input dilution factor; LPS, lipopolysaccharide.</p></fn></table-wrap-foot></table-wrap></floats-group></article>
